Ignacio Illán-Gala1, Victor Montal2, Jordi Pegueroles2, Eduard Vilaplana2, Daniel Alcolea2, Oriol Dols-Icardo2, Noemi de Luna2, Janina Turón-Sans2, Elena Cortés-Vicente2, Luis Martinez-Roman2, Maria Belén Sánchez-Saudinós2, Andrea Subirana2, Laura Videla2, Isabel Sala2, Isabel Barroeta2, Sílvia Valldeneu2, Rafael Blesa2, Jordi Clarimón2, Alberto Lleó2, Juan Fortea1, Ricard Rojas-García2. 1. From the Sant Pau Memory Unit (I.I.-G., V.M., J.P., E.V., D.A., O.D.-I., L.M.-R., M.B.S.-S., A.S., L.V., I.S., I.B., S.V., R.B., J.C., A.L., J.F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona; Neuromuscular Diseases Unit (N.d.L., J.T.-S., E.C.-V., R.R.-G.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) (N.d.L., J.T.-S., E.C.-V., R.R.-G.), Valencia; Barcelona Down Medical Center (I.I.G., L.V., J.F.), Fundació Catalana de Síndrome de Down, Barcelona; and Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (I.I.-G., V.M., J.P., E.V., D.A., O.D.-I., I.B., R.B., J.C., A.L., J.F.), CIBERNED, Madrid, Spain. iillan@santpau.cat jfortea@santpau.cat. 2. From the Sant Pau Memory Unit (I.I.-G., V.M., J.P., E.V., D.A., O.D.-I., L.M.-R., M.B.S.-S., A.S., L.V., I.S., I.B., S.V., R.B., J.C., A.L., J.F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona; Neuromuscular Diseases Unit (N.d.L., J.T.-S., E.C.-V., R.R.-G.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) (N.d.L., J.T.-S., E.C.-V., R.R.-G.), Valencia; Barcelona Down Medical Center (I.I.G., L.V., J.F.), Fundació Catalana de Síndrome de Down, Barcelona; and Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (I.I.-G., V.M., J.P., E.V., D.A., O.D.-I., I.B., R.B., J.C., A.L., J.F.), CIBERNED, Madrid, Spain.
Abstract
OBJECTIVE: To characterize the cortical macrostructure and microstructure of behavioral and cognitive changes along the amyotrophic lateral sclerosis (ALS)-frontotemporal dementia (FTD) continuum. METHODS: We prospectively recruited 88 participants with a 3T MRI structural and diffusion-weighted imaging sequences: 31 with ALS, 20 with the behavioral variant of FTD (bvFTD), and 37 cognitively normal controls. Participants with ALS underwent a comprehensive cognitive and behavioral assessment and were dichotomized into ALS without cognitive or behavioral impairment (ALSno-cbi; n = 12) and ALS with cognitive or behavioral impairment (ALScbi; n = 19). We computed cortical thickness and cortical mean diffusivity using a surface-based approach and explored the cortical correlates of cognitive impairment with the Edinburgh Cognitive and Behavioral ALS Screen. RESULTS: The ALSno-cbi and ALScbi groups showed different patterns of reduced cortical thickness and increased cortical mean diffusivity. In the ALSno-cbi group, cortical thinning was restricted mainly to the dorsal motor cortex. In contrast, in the ALScbi group, cortical thinning was observed primarily on frontoinsular and temporal regions bilaterally. There were progressive cortical mean diffusivity changes along the ALSno-cbi, ALScbi, and bvFTD clinical continuum. Participants with ALS with either cognitive or behavioral impairment showed increased cortical mean diffusivity in the prefrontal cortex in the absence of cortical thickness. CONCLUSIONS: Cortical mean diffusivity might be a useful biomarker for the study of extramotor cortical neurodegeneration in the ALS-FTD clinical spectrum. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the cortical microstructure correlates with cognitive impairment in the ALS-FTD continuum.
OBJECTIVE: To characterize the cortical macrostructure and microstructure of behavioral and cognitive changes along the amyotrophic lateral sclerosis (ALS)-frontotemporal dementia (FTD) continuum. METHODS: We prospectively recruited 88 participants with a 3T MRI structural and diffusion-weighted imaging sequences: 31 with ALS, 20 with the behavioral variant of FTD (bvFTD), and 37 cognitively normal controls. Participants with ALS underwent a comprehensive cognitive and behavioral assessment and were dichotomized into ALS without cognitive or behavioral impairment (ALSno-cbi; n = 12) and ALS with cognitive or behavioral impairment (ALScbi; n = 19). We computed cortical thickness and cortical mean diffusivity using a surface-based approach and explored the cortical correlates of cognitive impairment with the Edinburgh Cognitive and Behavioral ALS Screen. RESULTS: The ALSno-cbi and ALScbi groups showed different patterns of reduced cortical thickness and increased cortical mean diffusivity. In the ALSno-cbi group, cortical thinning was restricted mainly to the dorsal motor cortex. In contrast, in the ALScbi group, cortical thinning was observed primarily on frontoinsular and temporal regions bilaterally. There were progressive cortical mean diffusivity changes along the ALSno-cbi, ALScbi, and bvFTD clinical continuum. Participants with ALS with either cognitive or behavioral impairment showed increased cortical mean diffusivity in the prefrontal cortex in the absence of cortical thickness. CONCLUSIONS: Cortical mean diffusivity might be a useful biomarker for the study of extramotor cortical neurodegeneration in the ALS-FTD clinical spectrum. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the cortical microstructure correlates with cognitive impairment in the ALS-FTD continuum.
Authors: Ignacio Illán-Gala; Victor Montal; Sergi Borrego-Écija; Eduard Vilaplana; Jordi Pegueroles; Daniel Alcolea; Belén Sánchez-Saudinós; Jordi Clarimón; Janina Turón-Sans; Nuria Bargalló; Sofía González-Ortiz; Howard J Rosen; Maria Luisa Gorno-Tempini; Bruce L Miller; Albert Lladó; Ricard Rojas-García; Rafael Blesa; Raquel Sánchez-Valle; Alberto Lleó; Juan Fortea Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: Ammar Al-Chalabi; Ashley Jones; Claire Troakes; Andrew King; Safa Al-Sarraj; Leonard H van den Berg Journal: Acta Neuropathol Date: 2012-08-02 Impact factor: 17.088
Authors: Matthew D Cykowski; Suzanne Z Powell; Leif E Peterson; Joan W Appel; Andreana L Rivera; Hidehiro Takei; Ellen Chang; Stanley H Appel Journal: J Neuropathol Exp Neurol Date: 2017-05-01 Impact factor: 3.685
Authors: Ignacio Illán-Gala; Victor Montal; Sergi Borrego-Écija; Maria Luisa Mandelli; Neus Falgàs; Ariane E Welch; Jordi Pegueroles; Miguel Santos-Santos; Alexandre Bejanin; Daniel Alcolea; Oriol Dols-Icardo; Olivia Belbin; Mª Belén Sánchez-Saudinós; Nuria Bargalló; Sofía González-Ortiz; Albert Lladó; Rafael Blesa; Bradford C Dickerson; Howard J Rosen; Bruce L Miller; Alberto Lleó; Maria Luisa Gorno-Tempini; Raquel Sánchez-Valle; Juan Fortea Journal: Alzheimers Res Ther Date: 2022-02-09 Impact factor: 6.982
Authors: Elena Rodriguez-Vieitez; Victor Montal; Jorge Sepulcre; Cristina Lois; Bernard Hanseeuw; Eduard Vilaplana; Aaron P Schultz; Michael J Properzi; Matthew R Scott; Rebecca Amariglio; Kathryn V Papp; Gad A Marshall; Juan Fortea; Keith A Johnson; Reisa A Sperling; Patrizia Vannini Journal: Mol Psychiatry Date: 2021-09-29 Impact factor: 15.992
Authors: David Reyes-Leiva; Oriol Dols-Icardo; Sonia Sirisi; Elena Cortés-Vicente; Janina Turon-Sans; Noemi de Luna; Rafael Blesa; Olivia Belbin; Victor Montal; Daniel Alcolea; Juan Fortea; Alberto Lleó; Ricard Rojas-García; Ignacio Illán-Gala Journal: Front Neurol Date: 2022-01-18 Impact factor: 4.003